Journal of Neurochemistry

Cover image for Vol. 130 Issue 5

Edited By: Jörg Schulz

Impact Factor: 4.244

ISI Journal Citation Reports © Ranking: 2013: 63/251 (Neurosciences); 74/291 (Biochemistry & Molecular Biology)

Online ISSN: 1471-4159



Author Guidelines


Effective with the 2014 volume, this journal will be published in an online-only format.
We will continue to offer online publication and online reproduction of colour figures free of charge. We envision that the transition to online only will allow us to offer our authors an improved peer review and production service but if you do have any questions or concerns please feel free to contact us at jnc@wiley.com.


Did you know... Journal of Neurochemistry has no page charges?
Did you know... Journal of Neurochemistry allows Open Access publication?
Did you know... Journal of Neurochemistry makes review articles freely accessible from publication?

Download Author Guidelines
I
nstructions to Authors

During online submission at ScholarOne (http://mc.manuscriptcentral.com/jneurochem), you should have the following information ready:

  • Author/co-author affiliations (name, institution, department, city, email address)
  • Title, abstract, up to 6 keywords for the manuscript
  • Full name and valid email address of preferred /non-preferred referees and editors.
  • Cover letter to the Editor
  • Details of whether the manuscript is a resubmission (if yes, you will need to provide the previous manuscript ID), if it has color figures, if you are an ISN member, if the first author is below age 35 (for the manuscript to be eligible for the Mark A. Smith Award), info on funding, institutional approval, conflicts of interests
  • All manuscript files:
    • Main text file including figure and table legends as .doc, .docx or .rtf
    • Tables (may also be included at the end of the main text file)
    • Figures as .tiff, .eps or .pdf (one file per figure) with at least 300 dpi resolution
    • Supplementary Files, if any, merged into one single .pdf file wherever possible
    • Cover image suggestion, if any (at least 100 mm high/230 mm wide with 300 dpi resolution)
  • Manuscripts are restricted to a length of 7,500 words + ~6-7 figures and tables + references. The total word count [Abstract, Introduction, Methods, Results, Discussion, Acknowledgments, References] will be requested.

Full instructions are provided below. For assistance, please contact the Editorial Office.

I. GENERAL
II. MANUSCRIPT REQUIREMENTS
III. MISCELLANEOUS
IV. ACCEPTANCE

I. GENERAL

1. General
2. Paper Types
3. Submission of previously published material
4. Ethical considerations

1. Journal of Neurochemistry focuses on molecular, cellular and biochemical aspects of the nervous system, the pathogenesis of neurological disorders and the development of disease specific biomarkers. It is devoted to the prompt publication of original findings of the highest scientific priority and value that provide novel mechanistic insights, represent a clear advance over previous studies and have the potential to generate exciting future research. See: http://mc.manuscriptcentral.com/jneurochem.

2. Four types of papers are considered:

Original Articles (full papers) Short Communications Systematic reviews Narrative reviews
Format/stylePresent a definite new major finding of significant impact. Style described in section II. (Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments/ Conflict of interest disclosure, References, Figure legends) Provide a broad systematic analysis of resesarch in a specific field. Style as for Original Articles Unsolicited narrative reviews will be considered but subjected to rigorous editorial assessment. For review suggestions it is recommended to send first a synopsis to the Editor for Reviews. Should be authoritative and topical accounts of the subject area.
Length restriction 10 printed pages = 7,500 words + ~6-7 half-page figures and/or tables + references (no limit) 4 printed pages = 3,000 words incl. figure legends + max. 4 figures and/or tables (subtract 500 words for each additional figure) + references See Narrative Reviews 14 printed pages = 14,000 words (4,000-6,000 words for Mini Reviews) incl. references, figure legends, figures and/or tables (each half-page figure corresponds to about 500 words).
Supplements allowed not allowed allowed not allowed



3. Submission of previously published material

Submission of a paper to Journal of Neurochemistry will be held to imply that it represents original research not previously published (except as a meeting abstract, or written dissertation, or non peer-reviewed preliminary report - any of which to be explicitly stated and cited), that it is not being considered for publication elsewhere save the above mentioned exceptions, and that, if accepted, it will not be published elsewhere in similar form, in any language, without the consent of the International Society for Neurochemistry.

4. Ethical considerations

  • The research being reported should have been conducted in an ethical and responsible manner and should comply with all relevant legislation.
  • Researchers should present their methods and results clearly, unambiguously, honestly, and without fabrication, falsification or inappropriate data manipulation so that their findings can be confirmed by others. Submitted work should be original and not been published elsewhere.
  • The authorship of research publications should accurately reflect individuals’ contributions to the work and its reporting. Authors take collective responsibility for submitted and published work.
  • Funding sources and relevant conflicts of interest should be disclosed.



4.1 Ethical standards
(a) Authors are expected to abide by accepted ethical standards such as the COPE guidelines[1]:

Experiments should be carried out in accordance with the Guidelines laid down by the relevant National Agency. An according statement needs to be included into the methods. Editors reserve the right to reject papers if there is doubt whether appropriate procedures were followed.

(b) The Chief Editors of JNC expect corresponding authors to refer to the ‘ARRIVE’ guidelines for reporting research (www.nc3rs.org.uk/ARRIVE) before submission of a manuscript. While the guidelines refer to animal experiments, most of the elements are common to all forms of research communication and adherence will strengthen the transparency and completeness of reporting.

(c)  Journal of Neurochemistry uses iThenticate plagiarism software as part of the editorial process for manuscripts approaching acceptance. The software identifies matching text in different documents, which can highlight possible cases of plagiarism for the editorial office to investigate further. By submitting their manuscript to this journal authors accept that their manuscript may be screened for plagiarism against their own and others’ previously published works.

(d) Digital images in submissions will be scrutinized for any indication of manipulation that violates the following guidelines, such violation resulting in rejection of the manuscript:

  • Specific features within an image must not be enhanced, obscured, (re-)moved or introduced. Adjustments of brightness or contrast are only acceptable if they apply to every pixel in the image and as long as they do not misrepresent any information present in the original (including background). Non-linear adjustments, e.g. as changes in the gamma settings, must be stated.
  • Data sets that belong together, e.g. control condition and test condition or different parts from the same gel/blot, should be grouped together. Grouping of images from different gels, fields, exposures, experimental series etc. must be made explicit in the figure and its legend.

The corresponding author should submit documentation or explanation of any image enhancement used. The editors reserve the right to request submission of original unprocessed data from authors should questions arise about the appropriateness of any submitted material. Failure of providing it may result in rejection of the manuscript. Any case in which manipulation affects the interpretation of the data will result in revocation of acceptance. Cases of suspected misconduct will be reported to an author’s home institution or funding agency.

(e) The corresponding author takes responsibility for the integrity of the work as a whole, from inception to published article. It is assumed that all authors have seen and approved the submission.


[1] Developed by the Committee on Publication Ethics (COPE) during the 2nd World Conference on Research Integrity in Singapore in 2010 (see http://publicationethics.org/resources/international-standards)

See also: Wager E & Kleinert S (2011) Responsible research publication: international standards for authors. A position statement developed at the 2nd World Conference on Research Integrity, Singapore, July 22-24, 2010. Chapter 50 in: Mayer T & Steneck N (eds) Promoting Research Integrity in a Global Environment. Imperial College Press / World Scientific Publishing, Singapore (pp 309-16). (ISBN 978-981-4340-97-7).

4.2 Authorship

Authorship on a manuscript submitted to Journal of Neurochemistry should be based on the following criteria defined by the International Committee of Medical Journal Editors:

  1. substantial contribution to conception and design, data acquisition, analysis or interpretation;
  2. drafting the article or revising it critically for important intellectual content; and
  3. final approval of the version to be published.

If not all criteria are met, contributors should be listed with their respective contribution in the Acknowledgments instead.

4.3 Ethical violations: Definitions and sanctions

Any (suspected) ethical violation, error or mistake - as per the definitions below - reported for a manuscript submitted to or published in Journal of Neurochemistry will be investigated by the Editorial Board. Depending on the kind and severity of the reported problem, the following measures may be taken:

Retraction: A publication identified as having such significant concerns that the veracity of the described findings are unsafe or in doubt. A paper would only be retracted after consultation/agreement between the Chief Editor/Publication Committee, the authors and the publisher, and usually following formal investigation by the institution where the work was carried out and/or a national body.

Corrigendum: A significant error discovered after publication, and shown with its correction on a separate sheet. A solution usually initiated by the authors, with the approval of the publication committee and the publishers.

Erratum: Listing of a relatively minor error in a published work by tacit agreement between the authors, the publication committee, and the publishers.

(i) Data fabrication or plagiarism of data from others

For any work submitted to or already accepted in Journal of Neurochemistry for publication, fabricating or plagiarizing data from others will carry a ban on future submissions for up to the maximum of 8 years.

(ii) Duplicate publication and self-plagiarism

In the case of discernible duplicate publication/self-plagiarism the earliest version will stand as the publication of record and the editors of later versions will be responsible for applying sanctions against authors (below). In the case of duplicate submission/self-plagiarism the editors will not proceed with manuscript review, will inform each other, and apply appropriate sanctions:

Duplicate submission will carry a ban on future submissions for up to 2 years. Self-plagiarism of text, undisclosed conflict or ethical issues will carry anything from a reprimand up to a 2 year ban on submission.

For any work already accepted for publication in Journal of Neurochemistry, a ban on future submissions for up to the maximum of 8 years will be imposed.

4.4 Accessibility of data, materials and associated protocols

Nucleic acid and protein sequences, microarray data, ChIP sequences, proteomic data, metabolomic data, and other data obtained using high throughput sequencing techniques, as well as materials and associated protocols are important products of the scientific enterprise. Any material (including transgenic animals and antibodies) that is key to replication of the reported results must be accessible without undue restriction from the date of publication in order to allow others to replicate and build upon the authors’ claims for decades in the future. Any restriction on the access to material or data must be disclosed at the time of submission. Authors must investigate and disclose any restrictions associated with the human or other tissue they are using. Only material without legal, financial or other restrictions should be used. If the use of material mandates consent forms, any limits that result from those forms must be disclosed upon submission.

Readers who encounter refusal by the authors to comply with these policies should contact the Chief Editor. In cases where editors are unable to resolve a complaint, the journal may refer the matter to the authors' funding institution and/or publish a formal statement of correction, attached online to the publication, stating that readers have been unable to obtain necessary materials to replicate the findings.

4.4.1 Dataset Accessibility

Journal of Neurochemistry expects that data supporting the results in the paper are archived in an appropriate public archive, your own institutional or funder repository, or as Supporting Information on the Journal of Neurochemistry website. Examples of suitable databases are:

GenBank (http://www.ncbi.nlm.nih.gov/Genbank/index.html)
EMBL (http://www.ebi.ac.uk),
DNA Data Bank of Japan (http://www.ddbj.nig.ac.jp)
Protein Data Bank Japan (PDBj, http://www.pdbj.org)
Protein Databank (PDB, http://www.rcsb.org/pdb/)
Worldwide Protein Data Bank (wwPDB, http://www.wwpdb.org)
UniProtKB/Swiss-Prot (http://web.expasy.org/docs/swiss-prot_guideline.html)

Authors are expected to archive the complete dataset, along with sufficient details so that a third party can interpret them correctly. No data are to be withdrawn following publication. As discussed by Whitlock et al. (2010)[3], this will likely "require a short additional text document, with details specifying the meaning of each column in the data set. The preparation of such shareable data sets will be easiest if these files are prepared as part of the data analysis phase of the preparation of the paper, rather than after acceptance of a manuscript."

Microarray data should be MIAME compliant (see www.mged.org/Workgroups/MIAME/miame.html, FGED (The Functional Genomics Data) Society: MIAME (Minimum Information About a Microarray Experiment).

The public repositories ArrayExpress at the EBI (UK), GEO at NCBI (US) and CIBEX at DDBJ (Japan) are designed to accept, hold and distribute MIAME compliant microarray data.

The utility of archived data is greatly enhanced when the scripts and input files used in the analyses are also made available. Given that scripts may be a mix of proprietary and freely available code, their deposition is not compulsory, but we nonetheless strongly encourage authors to make these scripts available whenever possible.

Authors may elect to have the data publicly available at the time of publication, or, if the technology of the archive allows, may opt to embargo access to the data for a period up to a year after publication. Exceptions may be granted at the discretion of the editor, e.g. for sensitive information that might compromise the anonymity of human subjects.

An entry name or accession number, together with a direct link, should be included in a ‘Data Accessibility’ section at the end of the “Methods” section at initial submission if available. This should list the database and the respective accession numbers for all data from the manuscript that has been made publicly available. An example follows:

-DNA sequences: Genbank accessions F234391-F234402; NCBI SRA: SRX0110215
-Final DNA sequence assembly: uploaded as online supporting information
-Phylogenetic data: TreeBASE Study accession no. S9345
-R scripts: uploaded as online supporting information
-Sample locations, IMa2 input files and microsatellite data: DRYAD entry doi:10.5521/dryad.1311

Please note that reviewers may be asked to comment on the completeness of the Data Accessibility section.

For additional guidelines on data deposition best practice, please visit http://datadryad.org/depositing or http://data-archive.ac.uk/media/2894/managingsharing.pdf.

If you have any questions about the formatting of this section please contact JNC-CE@ukaachen.de

[3] Whitlock MC, McPeek MA, Rausher MD, Riesberg LR, Moore AJ (2010) Data archiving. American Naturalist, 175, 145-146.

4.4.2 New scientific/technological developments

Publication of descriptions of new recombinant nucleic acid or monoclonal antibody preparations, chemical compounds, but also (human or animal) cell lines or animal strains will be on the understanding that the authors are willing to supply samples of such materials in response to reasonable scientific requests, which can be defined in a Material Transfer Agreement to be signed by all involved parties. Payment to cover costs of distribution can be requested, and reagents may be made available via commercial or non-commercial third party providers. Information provided on compounds essential for the conclusions of the manuscript must be sufficient to allow others to reproduce them, e.g. describing chemical structure, synthesis and characterization.

II. MANUSCRIPT REQUIREMENTS

1. Layout
2. Copyright Transfer Agreement

1. Layout

Requirements for:Initial submission Revision
Text and figure requirements Prepare manuscript either containing all text, tables, figures and legends and supporting information in a single PDF

or,

in the format listed under "Revisions" (encouraged)

Upload

  1. point-by-point reply with specific reference to earlier reviewer an editor comments, indicating all changes introduced to the revision
  2. main text (.doc, .docx or .rtf) including all tables and figure legends, but no figures; highlight changes to the previous version
  3. figures as 300 dpi *.tiff, *.eps or *.pdf files (one file per figure)
  4. supporting information merged into one single PDF (except for video files etc. which cannot be converted into PDF format)
  5. graphical abstract for the In this issue section (~60 words describing background, main novel finding and implications of your study, accompanied by a summarizing schematic (*.tiff, 300 dpi resolution) that is explained by the text or self-explanatory; ensure you hold the copyright for the image
Suggestion of referees / handling editors Suggestions of referees are strongly encouraged (please indicate first name, middle initials (!), last name, valid (!) email address and institution). However there must be no conflicts of interest such as ongoing collaborations, recent joint publications etc. Non-preferred referees may be indicated as well. It is also encouraged to suggest preferred handling editors.
Footnotes Footnotes to the text should be used sparingly, should be indicated by superscript numbers, and typed with corresponding numbers on a separate sheet.
Figure & Table requirements
  • Figures and Tables should be constructed so that they, together with their captions and legends, will be intelligible with minimal reference to the text
  • Legends should be explanatory but concise; explain all symbols and indicate the number of independent data points (n) represented in the figure
  • Only in exceptional cases may the same data be published in a Table and a Figure.

Figures

  • Color artwork (online and in print) is published free of charge to the author.
  • The Publisher guarantees to reproduce electron micrographs to the satisfaction of the author.
  • Figures should normally be about twice the final size; in no case should the dimensions exceed 20 x 30 cm. Lettering must be large enough to be legible when reduced to single-column size. Use scale bars on micrographs.
  • Data may be presented in bar graphs where appropriate. Three-dimensional presentation is acceptable only for data with three variants.
  • Figures must be planned so as to avoid wasted white space.
  • It is not necessary for the scale on a coordinate to start at 0.
  • Upload Vector graphics (e.g. line artwork) in Encapsulated Postscript Format (EPS) or PDF, and bitmap files (e.g. halftones) in Tagged Image File Format (TIFF) with at least 300 dpi resolution at appropriate size. Vector graphics in metafile (.WMF) or pict (.PCT) format are ideally embedded within the body of the text file. See http://authorservices.wiley.com/submit_illust.asp for detailed information on our digital illustration standards.
  • Authors are encouraged to upload cover image suggestions (.tiff format, 300 dpi resolution at a minumum size of 100 mm height and 230 mm width).

Tables

  • Use the table function of a word processor rather than tabs and spaces.
  • Reference to footnotes should be made with superscript lowercase letters.
  • Each column of a Table should carry an appropriate heading.
  • Clearly indicate the units of measurement in the column headings of a Table or the coordinates of a Figure. If the unit of measurement is the same for all the data in a Table, it may be given in the caption or in a line to be printed immediately below the Table.
Manuscripts should be 1.5 to double-spaced throughout and with margins at least 2.5 cm wide. Pages should be numbered in succession, the title page being page 1. They should contain the following sections:
1) Title page
  • include title, authors names, author affiliations, laboratory of origin, address, telephone and fax numbers, email address of the person to whom proofs and reprint requests should be addressed, running title (up to 45 characters), up to 6 keywords, any necessary footnotes, and a list of abbreviations used in the text (see section III.6 for a list of abbreviations allowed without definition)
2) Title and Abstract
  • Provide an informative, concise title that contains important search words, is appealing to readers and reflects the most important/novel aspect of the ms.
  • Ensure your abstract does not exceed 200 words, does not include unexplained abbreviations apart from those allowed without definition, and reflects the objectives and novelty of the described study
  • Try to optimize both for keyword searches, see also: http://authorservices.wiley.com/bauthor/seo.asp, www.wiley.com/legacy/wileyblackwell/pdf/SEOforAuthorsLINKS.pdf. An example is provided below. Editors reserve the right to suggest modification.
3) Introduction
  • Avoid exhaustive reviews of the literature but give a brief (1,000-2,000 words) summary of the published literature, clearly stating the advances of the presented study over previous publications
3) Methods
  • Give sufficient detail to permit repetition of the work by others
  • Summarize and reference published procedures; do not describe them in detail unless they have been substantially modified. If the procedures used are described in detail in articles that are in press, copies of such unpublished articles must accompany the submitted manuscript.
  • Indicate sex and source of animals used in the study, if applicable, as well as institutional approval of experiments and compliance with ARRIVE guidelines
  • When human subjects are used, include a statement that the experiments were undertaken with the understanding and written consent of each subject, and that the study conforms with The Code of Ethics of the World Medical Association (Declaration of Helsinki), printed in the British Medical Journal (18 July 1964).
  • Group special chemicals etc. with their sources under a separate subheading Materials.
  • Provide rationale for choosing the particular treatment or experimental design, and describe how subjects were allocated to groups/ how trials were randomized, blinded etc. if applicable.
  • Briefly but explicitly state measures taken to minimize pain and discomfort
  • Include separate section on Statistical Analysis which must be adequate, based on a sufficient number of repetitions or samples, and be performed on the complete dataset rather than only a representative experiment.
4) Results
  • Describe findings without discussion of their significance
  • Experimental conclusions should normally be based on an adequate number of observations with statistical analysis of variance and the significance of differences.
  • Present data with clearly defined mean values with some measure of their dispersion (e.g. standard deviation or standard error, and range) and an indication, with appropriate symbols, of the statistical significance of differences from control values (e.g. *p).
5) Discussion
  • Assess the significance of the findings in relation to the status of the field
6) Acknowledgements / Conflict of interest disclosure
  • Include funding sources
  • Disclose in the Acknowledgments any potential sources of conflicts of interest (= any interest or relationship, financial or otherwise, that might be perceived as influencing an author’s objectivity and is directly relevant or indirectly related to the work described in the manuscript; include but are not limited to patent/stock ownership, membership of a company board of directors, membership of an advisory board or committee for a company, and consultancy for or receipt of speaker’s fees from a company). The existence of a conflict of interest does not preclude publication in this journal. If the authors have no conflict of interest to declare, this must also be stated.
  • It is the responsibility of the corresponding author to review this policy with all authors and to collectively list in the cover letter to the Editor-in-Chief, in the manuscript (under the Acknowledgment section), and in the online submission system ALL pertinent commercial and other relationships. For further information on what should be declared please also see the BMJ declaration and corresponding BMJ editorial - Beyond conflict of interest (BMJ 1998;317:291 - 2).
  • List persons who contributed to the work, but do not meet the criteria for authorship (see section 4.2 Authorship), with their respective contribution
7) References FORMATTING EXAMPLES BELOW
  • In the text, cite references by names of authors and year of publication.
  • In the reference section, list references in alphabetical order, except for papers by three or more authors, which should be grouped in chronological order after any other papers by the first author.
  • Names of all co-authors must be given followed by the year of publication, full title of the paper, name of the Journal (see below) and first and last page numbers.
  • Journal titles should be abbreviated in accordance with the List of Journals Indexed in Index Medicus (Superintendent of Documents, US Government Printing Office, Washington, DC 20402, USA, DHEW Publication No. 95-267).
  • The J Neurochem reference style for EndNote® can be downloaded from http://endnote.com/downloads/style/journal-neurochemistry, or from http://authorservices.wiley.com/jendnotes/#j.
  • Unpublished experiments, papers in preparation, etc., may be mentioned only in the text; they must not be included in the list of References.
  • Cite papers that have been accepted for publication in the References with the abbreviated name of the Journal followed by the words, in press. Indicate the date of acceptance of each such paper when the manuscript is submitted. If reference is made to papers in press (or submitted), such items must be uploaded online and labelled as 'supporting document, for information'.
  • Personal communications may be used only when written authorization from the communicator is submitted with the original manuscript; they may be mentioned only in the text, giving name of communicator.
;
8) Supporting Information
  • Peer-reviewed material (text, figures, tables, multimedia, datasets) directly relevant to the conclusions of an article that cannot be included in the published version owing to space or format constraints.
  • Supplements will be posted on JNC's web site upon acceptance and is linked to the article as supplied by the author. A proof is not made available prior to publication; for these reasons, submission is required in the final format.
  • The published article must be complete and self-explanatory without the supplementary information. Supporting information should enhance, but not be essential to, a reader's understanding of the paper. Cite Supporting Information within the article text, and include a descriptive legend.
  • For further information on recommended file types and requirements for submission, please visit: http://authorservices.wiley.com/bauthor/suppinfo.asp
  • Wherever possible merge multiple instances and formats of supporting information (tables, figures and appendices) into one single document (PDF file wherever possible). Video clips can be submitted online with RTF manuscripts [complete instructions can be found in the ScholarOne author center and here].


Reference examples:

Journal article: Semenova M. M., Maki-Hokkonen A. M., Cao J., Komarovski V., Forsberg K. M., Koistinaho M., Coffey E. T. and Courtney M. J. (2007) Rho mediates calcium-dependent activation of p38alpha and subsequent excitotoxic cell death. Nat. Neurosci. 10, 436-443.

Book chapter: Feenstra M. G. P. (2000) Dopamine and noradrenaline release in the prefrontal cortex in relation to unconditioned and conditioned stress and reward, in Progress in Brain Research, (Uylings H. B. M., Van Eden C. G., De Bruin J. P. C., Feenstra M. G. P. and Pennartz C. M. A., eds), Vol. 126, pp. 133-163. Elsevier Science B. V., Amsterdam.

Book: Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.

Book in series: Di Chiara G. and Gessa G. L., eds (1981) Advances in Biochemical Psychopharmacology, Vol. 27: Glutamate as a Neurotransmitter. Raven Press, New York.

Example for optimization of title and abstract:

Example of optimization of title and abstract

2. Copyright Transfer Agreement

If your paper is accepted, the author identified as the formal corresponding author for the paper will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper. If the OnlineOpen option is not selected the corresponding author will be presented with the copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be previewed in the samples associated with the Copyright FAQs below:

CTA Terms and Conditions http://authorservices.wiley.com/bauthor/faqs_copyright.asp

III. MISCELLANEOUS

1. Drug names
2. Enzymes
3. Solutions
4. Centrifugation
5. Abbreviations and Symbols
6. Nomenclature
7. Protein Sequences

1. Drug names

Drug names should be the official or approved names; trade names or common names may be given in brackets where the drug is first mentioned.

2. Enzymes

The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text. Subsequently, the accepted trivial name shall be used, e.g. full name: Acetyl-CoA, choline O-acetyltransferase (EC 2.3.1.6), trivial name: choline acetyltransferase not choline acetylase. For this information the author should refer to Enzyme Nomenclature (1992), Academic Press, San Diego and London. (Units of enzyme activity should be defined in terms of the rate of the reaction catalyzed under specified conditions.) The official Système Internationale (SI) unit is the katal, i.e. mol of substrate transformed (or product formed)/s. However, it may be expressed in other terms, provided clear definitions are given, e.g. µmol/s or µmol/min.

3. Solutions

Although SI recommends concentrations to be expressed as mol/L rather than M and that % (wt/vol) and % (vol/vol) should be given as g/L and mL/L, respectively, the use of M, % (wt/vol), and % (vol/vol) will be allowed. N is not permitted. Fractional concentrations should be expressed in decimal form.

4. Centrifugation

Centrifugation conditions should be expressed in terms of g and time; not in revolutions per minute.

5. Abbreviations and Symbols

(a) The use of abbreviations should be restricted to the Système Internationale (SI) units, see Biochem. J. (1978) 169, 1-27, and a minimum of other generally accepted terms [see (b)]. Excessive use of abbreviations in the text is discouraged.

(b) The following abbreviations may be used without definition.

ADPCDP, GDP, IDP, UDP, 5(pyro)-diphosphates of adenosine, cytidine, guanosine, inosine, uridine, etc.
AMP -5-phosphates of adenosine, etc.
ATP -5`(pyro)-triphosphates of adenosine, etc.
ATPase adenosine triphosphatase
ANOVA analysis of variance
bp base pair
Ci curie
CoA and acyl-CoA coenzyme A and its acyl derivatives (e.g., acetyl-CoA)
cAMP 3,5-cyclic adenosine monophosphate, etc.
cpm counts per minute
CNS central nervous system
CSF cerebrospinal fluid
DNA deoxyribonucleic acid
DNase deoxyribonuclease
DOPA 3,4-dihydroxyphenylalanine
dpm dps-disintegrations per minute/second
EDTA ethylene-diaminetetraacetate
EEG electroencephalogram
EGTA Ethyleneglycol-bis(aminoethylether)tetraacetate
ELISA enzyme-linked immunosorbent assay
FAD, FADH2 flavin-adenine dinucleotide and its reduced form
FMN flavin mononucleotide
g average gravity
GABA gamma-aminobutyric acid (not Gaba)
GLC gas-liquid chromatography
GSSG, GSH glutathione, oxidized and reduced forms
h hour
HEPES N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
HPLC high performance liquid chromatography
Ig immunoglobulin
IR infrared
Kb kilobase
kDa kilodalton
µm micron
min minute
MPP+ 1-methyl-4-phenylpyridinium
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NAD+ NADH-oxidized and reduced forms of nicotin-amide-adenine dinucleotide
NADP+ NADPH-oxidized and reduced forms of nicotin-amide-adenine dinucleotide phosphate
NAD NADP may be used when the oxidation state need not be indicated
NMDA N-methyl-D-aspartate
NMN nicotinamide mononucleotide
NMR nuclear magnetic resonance
PCR polymerase chain reaction
Pi orthophosphate (inorganic)
PNS peripheral nervous system
PPi pyrophosphate (inorganic)
rpm revolutions per minute
RNA ribonucleic acid
RNase ribonuclease
RT reverse transcription
s second
SEM standard error of mean
SD standard deviation
TLC thin-layer chromatography
Tris 2-amino-2-hydroxy-methylpropane-1,3-diol
UV ultraviolet

(c) Other abbreviations may be used sparingly and defined in a footnote on the title page, as well as at their first mention in text. Recommended forms of abbreviation to be used with definition are as follows:

ACh, acetylcholine; AChE, acetylcholinesterase; AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate; ChAT, choline acetyltransferase; COMT, catechol-O-methyltransferase; DA, 3,4-dihydroxyphenylethylamine or dopamine; 5-HT, 5-hydroxytryptamine or serotonin; MAO, monoamine oxidase; NA, noradrenaline, norepinephrine; NeuNAc, N-acetylneuraminic acid (not NANA)


6. Nomenclature

Authors should follow the nomenclature recommended by the International Union of Basic and Clinical Pharmacology (IUPHAR) and the IUPAC-IUB Joint Commission on Biochemical Nomenclature. For references to these rules see Biochemical Nomenclature and Related Documents 2nd edit. (1992), available from Portland Press Ltd., 59 Portland Place, London W1N 3AJ, UK or Portland Press Inc., PO Box 2191, Chapel Hill, NC 27515-2191, USA.

7. Protein Sequences

Protein sequences, which have been determined by direct sequencing of the protein, must be submitted to SWISS-PROT at the EMBL Outstation - The European Bioinformatics Institute. Please note that we do not provide accession numbers, IN ADVANCE, for protein sequences that are the result of translation of nucleic acid sequences. These translations will automatically be forwarded to us from the EMBL nucleotide database and are assigned SWISS-PROT accession numbers on incorporation into TrEMBL.

Results from characterization experiments should also be submitted to SWISS-PROT at the EBI. This can include such information as function, subcellular location, subunit etc.

Contact information: SWISS-PROT Submissions, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK. Tel: +44 (0)1223 494400; Fax: +44 (0)1223 494472. Email: datasubs@ebi.ac.uk (for sequence admissions) update@ebi.ac.uk (for characterization information) Website: www.ebi.ac.uk

IV. ACCEPTANCE

1. OnlineOpen / Open Access
2. Proofs
3. Offprints
4. Digitisation of JNC
5. Accepted Articles (“Early Online”)
6. Enquiries concerning papers in press
7. Online production tracking
8. NIH-funded authors and Journal of Neurochemistry

1. OnlineOpen / Open Access

Contributors to this journal may choose to make their articles open access and available free for all readers. For options, see: http://olabout.wiley.com/WileyCDA/Section/id-406241.html.

OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.

Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://authorservices.wiley.com/bauthor/onlineopen_order.asp

Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

For authors choosing OnlineOpen

 If the OnlineOpen option is selected the corresponding author will have a choice of the following Creative Commons License Open Access Agreements (OAA):

Creative Commons Attribution License OAA
Creative Commons Attribution Non-Commercial License OAA
Creative Commons Attribution Non-Commercial -NoDerivs License OAA

To preview the terms and conditions of these open access agreements please visit the Copyright FAQs hosted on Wiley Author Services http://authorservices.wiley.com/bauthor/faqs_copyright.asp and visit http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html.

If you select the OnlineOpen option and your research is funded by The Wellcome Trust and members of the Research Councils UK (RCUK) or the Austrian Science Fund (FWF) you will be given the opportunity to publish your article under a CC-BY license supporting you in complying with your Funder requirements. For more information on this policy and the Journal’s compliant self-archiving policy please visit: http://www.wiley.com/go/funderstatement.

2. Proofs

All information about the proofs will be sent to the author submitting the paper and corrected proofs must be returned promptly. This will allow correction of typesetters and similar errors. Authors will be sent an email alerting them that proofs are available to download from our secure designated author website. Authors who fail to download the proofs will be sent their proofs via email as an Acrobat PDF (portable document format) file. Therefore, the corresponding author should supply their email address when they submit their manuscript. The email server must be able to accept attachments up to 4 MB in size. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following Web site: http://get.adobe.com/uk/reader/

To assure prompt publication, proofs should be returned not more than 3 working days after receipt. Corrections should be restricted to typesetter errors and completion of in press references.

Substantial alterations to proofs may delay publication and also be charged to authors.

3. Offprints

Free access to the final PDF offprint of your paper will be available via author services only. Authors may therefore sign up for author services if they would like to access their article PDF offprint and enjoy the many other benefits this service offers. Paper offprints may be ordered at prices quoted on the order form, which accompanies proofs, provided that the form is returned with the proofs. The cost is more if the order form arrives too late for the main print run. Offprints are normally dispatched within three weeks of publication of the issue in which the paper appears. The publisher may be contacted if offprints do not arrive. Offprints are sent by surface mail.

4. Digitisation of JNC

Wiley-Blackwell and The International Society for Neurochemistry have digitised the entire run of JNC back to volume one, issue one. The back files, which have been defined as all of those issues published before 1997, will be sold to libraries as part of Wiley-Blackwell's Publishing's Legacy Sales Programme and hosted on the Wiley Online Library.

5. Accepted Articles (“Early Online”)

Journal of Neurochemistry offers Accepted Articles. Accepted Articles have been accepted for publication and undergone full peer review but have not been through the copyediting, typesetting, pagination and proofreading process. Accepted Articles are published online a few days after final acceptance, appear in PDF format only, are given a Digital Object Identifier (DOI), which allows them to be cited and tracked, and are indexed by PubMed. A completed copyright form is required before a manuscript can be processed as an Accepted Article. Graphics are placed at the end of the PDF and may be compressed to reduce download time of the PDF. Once the manuscript has been through the production process (approximately 30 days) the article is removed from the Accepted Articles area and published as normal.

6. Enquiries concerning papers in press

All enquiries concerning the status of manuscripts accepted for publication should be directed to: Production Editors, Journal of Neurochemistry, John Wiley & Sons Singapore Pte. Ltd, 1 Fusionopolis Walk, #07-01 Solaris South Tower, Singapore 138628 (Email: jnc@wiley.com)

7. Online production tracking

This is now available for articles through Wiley-Blackwell's Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated emails at key stages of production. The author will receive an email with a unique link that enables them to register and have their article automatically added to the system. Please ensure that a complete email address is provided when submitting the manuscript. Visit http://authorservices.wiley.com/bauthor/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.

8. NIH-funded authors and Journal of Neurochemistry

The NIH mandates grantees to deposit their peer-reviewed author manuscripts in PubMed Central, to be made publicly available within 12 months of publication. The NIH mandate applies to all articles based on research that has been wholly or partially funded by the NIH and that are accepted for publication on or after April 7, 2008. In order to help authors comply with the NIH mandate, for papers accepted for publication in Journal of Neurochemistry, Wiley-Blackwell will post the accepted manuscript (incorporating all amendments made during peer review, but prior to the publisher's copy-editing and typesetting) of articles by NIH grant-holders to PubMed Central at the point of acceptance by the journal. This version will then be made publicly available in PubMed Central 12 months after publication. Following the deposit Wiley-Blackwell authors will receive further communications from the NIH with respect to the submission. For further information, see here.

If authors wish to make their final published article openly accessible and without a 12 month embargo, they can choose to publish via the OnlineOpen service.

Wellcome and HHMI grantees can find out further information here.

Author Guidelines last updated 11 July 2014

SEARCH

SEARCH BY CITATION